FDA Advisory Panel Recommends Approval of At-Home Colon Cancer Test
FRIDAY, March 28, 2014 (HealthDay News) -- A panel of U.S. Food and Drug Administration experts on Thursday unanimously recommended approval of a new at-home stool test that screens for colorectal cancer with more than 90 percent accuracy.
The 10-member committee said the benefits of Exact Science Corp.'s Cologuard test outweigh its risks, the Associated Press reported. The FDA is not obligated to follow its panels' recommendations, but usually does.
The panel's blessing comes on the heels of a study published earlier this month that found Cologuard had a very high accuracy rate in spotting colon cancer.
Last year, nearly 143,000 new cases of colorectal cancer were diagnosed in the United States and almost 50,000 Americans died of the disease, according to the U.S. National Cancer Institute.
Yet, one-third of Americans fail to heed public health recommendations to undergo more invasive colonoscopy screenings every 10 years starting at age 50, said study co-author Dr. Steven Itzkowitz, director of the gastroenterology fellowship program at the Icahn School of Medicine at Mount Sinai in New York City
Commonly used stool tests such as FIT (fecal immunochemical testing) rely on detecting blood in the stool. The new Cologuard test checks for blood as well as abnormal DNA coming from the tumor, "with the advantage that some lesions, even cancers, don't bleed very much," Itzkowitz explained.
The Cologuard test also features a DNA analysis not included in other fecal exams.
"By increasing the pick-up rate in this way," said Itzkowitz, "we found that the new test had a 92 percent sensitivity for detection of colorectal cancer. That kind of result is really unprecedented for a noninvasive stool-based screening."
The research, published in the March 19 issue of the New England Journal of Medicine, was funded by Exact Sciences, which is based in Wisconsin.
To assess the potential of the DNA method, nearly 10,000 men and women aged 50 and older were screened for colon cancer and precancerous polyps at one of 90 sites across the United States and Canada. All were considered at average risk for colon cancer.
Each patient was screened three ways: by means of a standard colonoscopy; a commercially available fecal test (FIT); and the new DNA test, which requires patients to collect their own stool sample at home and mail it in for laboratory analysis.
In the end, colonoscopy screenings -- considered the gold standard of colon cancer screening -- unearthed colon cancer in 65 participants, while another 757 were found to have advanced precancerous lesions.
The new test accurately detected 60 of those 65 cancers. The FIT test spotted only 48 cancers, with an accuracy rate of 74 percent compared to 92 percent for the new test.
The DNA test was less accurate with respect to precancerous lesions, spotting about 42 percent of cases. Yet that still topped FIT, which detected roughly 24 percent of precancerous lesions. Cologuard's sensitivity was 69 percent for precancerous polyps most likely to progress to cancer versus 46 percent for the FIT test.
However, the DNA test was more likely to falsely suggest the presence of cancer than either a colonoscopy or FIT testing.
"It's not a perfect test," Itzkowitz acknowledged. "But neither is a colonoscopy. Also, I don't think we're saying that this test should be done as a replacement for a colonoscopy, but rather as an adjunct. Certainly if a person who does this test comes out with a positive reading then they will need to do a colonoscopy afterwards to confirm it."
Dr. Frank Sinicrope, a professor of medicine and oncology at the Mayo Clinic in Rochester, Minn., said "these data demonstrate the superiority of stool DNA testing compared to FIT for colorectal cancer screening."
Sinicrope, who was not part of the study team, also suggested that the Cologuard method might offer some advantages over standard colonoscopies.
In particular, he pointed to the DNA test's success in identifying certain advanced-stage polyps, noting such precancerous growths are typically flat and "located in the right side of the colon and are difficult to detect at colonoscopy."
Nevertheless, Sinicrope said there are still "important issues that await further research." Those would include determining how best to deal with false positive results and establishing how often patients should take the DNA test to maximize its screening potential.
For more information on colorectal cancer visit the U.S. National Cancer Institute.
SOURCES: Steven Itzkowitz, M.D., professor, medicine, director, gastroenterology fellowship program, Icahn School of Medicine at Mount Sinai, New York City; Frank Sinicrope, M.D., professor, medicine and oncology, Mayo Clinic, Rochester, Minn.; March 19, 2014, New England Journal of Medicine, Associated Press